AAPL   375.45 (+0.43%)
MSFT   211.40 (+0.33%)
FB   243.65 (+1.40%)
AMZN   3,027.20 (-0.98%)
NVDA   398.93 (+1.36%)
CGC   16.59 (-2.12%)
MU   49.71 (-2.40%)
GE   6.82 (-2.57%)
TSLA   1,396.95 (+1.85%)
AMD   53.28 (-0.22%)
T   30.40 (-0.30%)
GILD   76.63 (-0.17%)
BAC   23.05 (-2.58%)
NFLX   492.31 (-0.30%)
BA   181.57 (-3.37%)
AAPL   375.45 (+0.43%)
MSFT   211.40 (+0.33%)
FB   243.65 (+1.40%)
AMZN   3,027.20 (-0.98%)
NVDA   398.93 (+1.36%)
CGC   16.59 (-2.12%)
MU   49.71 (-2.40%)
GE   6.82 (-2.57%)
TSLA   1,396.95 (+1.85%)
AMD   53.28 (-0.22%)
T   30.40 (-0.30%)
GILD   76.63 (-0.17%)
BAC   23.05 (-2.58%)
NFLX   492.31 (-0.30%)
BA   181.57 (-3.37%)
AAPL   375.45 (+0.43%)
MSFT   211.40 (+0.33%)
FB   243.65 (+1.40%)
AMZN   3,027.20 (-0.98%)
NVDA   398.93 (+1.36%)
CGC   16.59 (-2.12%)
MU   49.71 (-2.40%)
GE   6.82 (-2.57%)
TSLA   1,396.95 (+1.85%)
AMD   53.28 (-0.22%)
T   30.40 (-0.30%)
GILD   76.63 (-0.17%)
BAC   23.05 (-2.58%)
NFLX   492.31 (-0.30%)
BA   181.57 (-3.37%)
AAPL   375.45 (+0.43%)
MSFT   211.40 (+0.33%)
FB   243.65 (+1.40%)
AMZN   3,027.20 (-0.98%)
NVDA   398.93 (+1.36%)
CGC   16.59 (-2.12%)
MU   49.71 (-2.40%)
GE   6.82 (-2.57%)
TSLA   1,396.95 (+1.85%)
AMD   53.28 (-0.22%)
T   30.40 (-0.30%)
GILD   76.63 (-0.17%)
BAC   23.05 (-2.58%)
NFLX   492.31 (-0.30%)
BA   181.57 (-3.37%)
Log in

NASDAQ:VCELVericel Stock Price, Forecast & News

$14.83
+0.03 (+0.20 %)
(As of 07/7/2020 02:33 PM ET)
Add
Compare
Today's Range
$14.52
Now: $14.83
$15.06
50-Day Range
$13.03
MA: $14.39
$15.11
52-Week Range
$6.78
Now: $14.83
$19.95
Volume224,596 shs
Average Volume637,861 shs
Market Capitalization$668.98 million
P/E RatioN/A
Dividend YieldN/A
Beta2.97
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Read More
Vericel logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.69 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCEL
CUSIPN/A
Phone617-588-5555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.85 million
Cash Flow$0.20 per share
Book Value$2.49 per share

Profitability

Net Income$-9,660,000.00

Miscellaneous

Employees216
Market Cap$668.98 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.

Vericel (NASDAQ:VCEL) Frequently Asked Questions

How has Vericel's stock been impacted by COVID-19 (Coronavirus)?

Vericel's stock was trading at $12.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VCEL stock has increased by 23.3% and is now trading at $14.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vericel?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vericel.

When is Vericel's next earnings date?

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Vericel.

How were Vericel's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.02. The biotechnology company earned $26.70 million during the quarter, compared to analyst estimates of $26.23 million. Vericel had a negative net margin of 9.39% and a positive return on equity of 5.87%. The business's revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.07) earnings per share. View Vericel's earnings history.

What price target have analysts set for VCEL?

5 brokers have issued 1 year price objectives for Vericel's stock. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's share price to reach $24.25 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price. View analysts' price targets for Vericel.

Has Vericel been receiving favorable news coverage?

News articles about VCEL stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vericel earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Vericel.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Amarin (AMRN), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), NVIDIA (NVDA), Verastem (VSTM), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

Who are Vericel's key executives?

Vericel's management team includes the following people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
  • Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $14.89.

How big of a company is Vericel?

Vericel has a market capitalization of $671.69 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

What is Vericel's official website?

The official website for Vericel is www.vcel.com.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.